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Two high-affinity, G protein-coupled melatonin receptor subtypes have been identified in mammals. Tar-
geted disruption of the Mel1a melatonin receptor prevents some, but not all, responses to the hormone,
suggesting functional redundancy among receptor subtypes (Liu et al., Neuron 19:91-102, 1997). In the present
work, the mouse Mel1b melatonin receptor cDNA was isolated and characterized, and the gene has been
disrupted. The cDNA encodes a receptor with high affinity for melatonin and a pharmacological profile
consistent with its assignment as encoding a melatonin receptor. Mice with targeted disruption of the Mel1b
receptor have no obvious circadian phenotype. Melatonin suppressed multiunit electrical activity in the
suprachiasmatic nucleus (SCN) in Mel1b receptor-deficient mice as effectively as in wild-type controls. The
neuropeptide, pituitary adenylyl cyclase activating peptide, increases the level of phosphorylated cyclic AMP
response element binding protein (CREB) in SCN slices, and melatonin reduces this effect. The Mel1a receptor
subtype mediates this inhibitory response at moderate ligand concentrations (1 nM). A residual response
apparent in Mel1a receptor-deficient C3H mice at higher melatonin concentrations (100 nM) is absent in
Mel1a-Mel1b double-mutant mice, indicating that the Mel1b receptor mediates this effect of melatonin. These
data indicate that there is a limited functional redundancy between the receptor subtypes in the SCN. Mice
with targeted disruption of melatonin receptor subtypes will allow molecular dissection of other melatonin
receptor-mediated responses.
The hormone, melatonin, is produced rhythmically in the
vertebrate pineal gland (13). Rhythmic melatonin production
plays a critical role in the regulation of reproduction in sea-
sonally breeding mammals (1, 24). In nonmammalian verte-
brates, melatonin also plays a major role in the regulation of
circadian rhythms (4, 46). While endogenous melatonin ap-
pears to play only a subtle role in the regulation of circadian
rhythms in mammals, exogenous melatonin influences circa-
dian rhythms in several rodent species and in humans (2, 3, 9,
21, 22, 39, 46, 47). While the magnitude of this phase shifting
effect is small for adult mammals, it is nevertheless critical in
some situations; e.g., daily melatonin administration appears
to be useful for entrainment of non-24-h circadian cycles to the
24-hour day for blind individuals (22).
Two high-affinity receptors for melatonin have been identi-
fied in mammals (for reviews, see references 33 and 43). These
receptors, the Mel1a and Mel1b receptor subtypes, are mem-
bers of the G protein-coupled receptor superfamily (29, 30). A
melatonin receptor-related receptor (also called H9 and
GPR50) has sequence homology to the Mel1a and Mel1b re-
ceptors but does not bind melatonin (7, 16, 32). In addition to
these three members of the gene family in mammals, nonmam-
malian species have a third high-affinity melatonin receptor
subtype, the Mel1c receptor (31). The mammalian Mel1a and
Mel1b receptors are also called the MT1 and MT2 receptors,
respectively [10]. The inability of this MT nomenclature system
to accommodate the nonmammalian Mel1c receptor has re-
sulted in persistence of dual nomenclature systems; here, we
use the original nomenclature.
The relative importance of the mammalian melatonin recep-
tor subtypes in mediating circadian responses to the hormone
is unclear. The circadian clocks of neonatal hamsters are very
efficiently set by even a single injection of melatonin, and
several physiological and in vitro responses of the suprachias-
matic nucleus (SCN) to melatonin have been observed in ham-
sters (25, 36, 39, 47). Remarkably, however, the Mel1b receptor
gene of several hamster species, including those with robust
circadian and reproductive responses to the hormone, does not
encode a functional melatonin receptor (47; see also GenBank
accession number AY145849). Pharmacological studies with
mice, however, suggest that the mouse Mel1b receptor medi-
ates circadian responses (9, 19). Other data, derived from mice
with targeted disruption of the Mel1a melatonin receptor, in-
dicate that this subtype mediates an acute suppressive effect of
melatonin on SCN neuronal firing, and they reveal apparent
redundancy of receptor subtypes in mediating the phase shift-
ing response to melatonin (23).
To determine whether the mouse Mel1b receptor contributes
* Corresponding author. Present address: Department of Neurobi-
ology, Lazare Research Building, Room 723, University of Massachu-
setts Medical School, 364 Plantation St., Worcester, MA 01605-2324.
Phone: (508) 856-2495. Fax: (508) 856-6266. E-mail: david.weaver
@umassmed.edu.
† Present address: CombinatoRx Inc., Boston, MA 02118.
‡ Present address: Department of Neurobiology, University of Mas-
sachusetts Medical School, Worcester MA 01605-2324.
1054
 o
n
 Septem
ber 12, 2012 by UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
to responses to the hormone, the mouse Mel1b receptor cDNA
was isolated. Finding that the mouse Mel1b receptor cDNA
encodes a high-affinity melatonin receptor, we then disrupted
the Mel1b receptor gene. Analysis of the mutant mice indicates
that the Mel1b receptor encodes a functionally relevant mela-
tonin receptor. The Mel1b receptor appears to mediate a re-
sponse to the hormone occurring at higher ligand concentra-
tions in mice lacking the Mel1a melatonin receptor.
MATERIALS AND METHODS
Isolation and characterization of the mouse Mel1b receptor cDNA. A fragment
of the mouse Mel1b receptor cDNA isolated by PCR has been previously re-
ported (47). A probe based on this published sequence was used to screen mouse
genomic DNA libraries, resulting in isolation of two overlapping genomic clones
containing exon 2 (A341 and A351). Genomic DNA encoding exon 1 was iso-
lated from a bacterial artificial chromosome library (Research Genetics, Inc.)
screened with the most 5 end of the intronic sequence from clone A341. In
addition, PCR amplification of mouse brain cDNA was performed using primers
spanning the intron, to confirm the splicing pattern, as well as along the cDNA
to confirm the sequence. A full-length cDNA was isolated by PCR using an
overlap-PCR method to “stitch” together exons 1 and 2, producing a silent
mutation at the slice site. The integrity of the cDNA construct was confirmed by
sequence analysis and compared to the sequence of genomic clones.
Genomic DNA sequence corresponding to the mouse Mel1b receptor locus
has recently been deposited in GenBank. GenBank accession no. NW_000351
represents a genomic contig including the mouse Mel1b receptor locus. The
deduced amino acid sequence of the receptor cDNA (GenBank accession no.
XM_146818), based on inferred splicing patterns using GenomeScan, differs
from that determined above due to the detection of two apparent exons within
intron 1, disruption of exon 2 by an apparent intron, and splicing to an additional
exon just 5 of the actual stop codon. Both homology with other members of the
melatonin receptor gene family and the RT-PCR data support the conclusion
that the Mel1b receptor locus consists of two exons.
When the nucleotide sequences are translated using a two-exon model, the
deduced amino acid sequence of the Mel1b receptor cDNA reported in GenBank
(AAL85489 and NW_000351) still differs from our sequence, due to the apparent
insertion of two nucleotides in exon 2 in the portion of sequence encoding the
carboxyl terminus of the protein in the GenBank entry. The accuracy of the
sequence reported here is supported by homology of our deduced amino acid
sequence with the human and Northern pike Mel1b receptor sequences (12) and
is confirmed by the identity of our sequence with the sequence entry in the
Celera database (entries mCT7575 and mCG8325). (The only amino acid dif-
ference between the sequence reported here and in the Celera database is T237
of our sequence, which is E237 in the Celera and other sequences.) We cannot
exclude the possibility that strain differences or other polymorphisms in the
genetic sequence exist.
Ligand binding characteristics. To compare the affinity and specificity of the
mouse Mel1a and Mel1b receptors, the characteristics of these receptor cDNAs
were examined in parallel in transiently transfected COS7 cells. Ligand binding
studies were conducted using the radioligand 2-[125I]iodomelatonin (125I-MEL)
as previously described (29, 34). Saturation binding experiments were conducted
with ligand concentrations ranging from 10 to 1,800 pM. Data were analyzed
using Kaliedograph software. Competitive inhibition studies were conducted
using 125I-MEL concentrations of 110 to 150 pM. Ki values were calculated from
50% inhibitory concentration (IC50) values using the Cheng-Prusoff equation
(5): Ki  IC50/(1  ([ligand]/Kd)).
Targeting disruption of the Mel1b receptor gene. A targeting construct was
generated in which the first exon of the Mel1b receptor gene was disrupted by
insertion of a neomycin resistance cassette at a SmaI site in exon 1 (Fig. 1). The
cassette (PGK-Neo) consists of the phosphoglycerate kinase (PGK) promoter
and a neomycin resistance gene and was placed in reverse orientation. The 5
arm was 2.2 kb; the 3 arm was 7 kb. The targeting construct was introduced into
FIG. 1. Mel1b receptor gene, targeting construct, and genotyping strategies. (A) Schematic of the Mel1b receptor gene and the targeting
construct. A neomycin resistance gene driven by the phosphoglycerate kinase promoter (PGK-Neo cassette) was inserted in reverse orientation
at the SmaI site within exon 1 of the mouse Mel1b receptor gene. The 5 and 3 arms of the targeting construct were 2.2 and 7 kb, respectively.
(B) Genotyping by Southern blot. A BamHI restriction site introduced with the PGK-Neo cassette formed the basis for genotyping by Southern
blotting, using a probe (solid bar in panel A) located outside the 5 end of the construct. Following digestion with BamHI, the probe hybridizes
to a ca. 10-kb band in wild-type DNA and a ca. 7-kb band for the targeted allele. Genotypes are shown above the lanes. Lanes illustrate the
hybridization pattern of wild-type (W), heterozygous mutant (H), and homozygous Mel1b-receptor mutant (knockout [K]) mice. Approximate sizes
of the genomic fragments are indicated at the left. (C) Strategy for genotyping by PCR. Magnified view of the relationship of the primers (arrows)
to the nucleotide sequences of the Mel1b receptor gene and the PGK-Neo cassette. (D) Genotyping by PCR. Amplification of mouse genomic DNA
with a cocktail of three primers led to amplification of distinct bands representing the wild-type and targeted alleles. Genotypes are shown above
the lanes; designations are as in panel B. Size markers on the left indicate bands at 910, 540, 426, 409, 266, and 166 bp, generated by pUC19 and
digested with DdeI.
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J1 embryonic stem cells by electroporation at the Massachusetts General Hos-
pital Knockout Core facility (En Li, director). For screening, DNA from neo-
mycin-resistant colonies was digested with BamHI and assessed by Southern
blotting, using a nonoverlapping 0.8-kb SstI fragment flanking the 5 end of the
construct as a probe. The targeting event was confirmed by digestion of embry-
onic stem cell DNA with EcoRI, followed by hybridization with a nonoverlapping
probe (based on exon 2) from the 3 flanking region as a probe (data not shown).
A clone with the appropriate banding pattern on Southern blot analysis (#83)
was microinjected into blastocysts by the Knockout Core facility. Chimeric mice
were bred to females of strain 129/sv, provided by En Li. Heterozygous offspring
were bred together to generate isogenic Mel1b receptor-deficient and wild-type
lines on the 129/sv background.
Southern blot analysis of tail DNA confirmed the targeting event (Fig. 1B).
For colony maintenance, mice were genotyped using PCR (Fig. 1C and D).
Reactions were performed using a mixture of three primers, allowing detection
of both wild-type and targeted alleles in a single reaction (Fig. 1C). A common
forward primer in exon 1 (mus1b5-4, CCAGGCCCCCTGTGACTGCCCGGG)
and a gene-specific reverse primer from intron 1 (mus1b3-3, 5 CCTGCCACT
GAGGACAGAACAGGG 3) amplified a 272-bp fragment from the wild-type
allele. The common forward primer and a reverse primer based on the sequence
of the 3 end of the PGK-Neo cassette (neo6-2, TGCCCCAAAGGCCTACC
CGCTTCC) amplified a ca. 550-bp fragment from the targeted allele. Amplifi-
cation of genomic DNA extracted from tail biopsies was performed using Taq
DNA polymerase and a program of 3 min at 94°C for initial denaturation,
followed by 35 cycles of denaturation at 94°C (30 s), annealing at 60°C (30 s), and
extension at 72°C (1 min). Products were separated on agarose gels and visual-
ized with ethidium bromide using UV trans-illumination (Fig. 1D).
Generation of melatonin receptor-deficient lines on a C3H/He genetic back-
ground. Mice with targeted disruption of the Mel1a receptor have been previ-
ously described (23). In these mice, exon 1 of the Mel1a receptor gene has been
replaced with the PGK-neomycin cassette. To generate animals with the receptor
targeting events on a consistent genetic background, a Mel1a receptor-deficient
male mouse with a hybrid, 129/sv  C57BL/6 genetic background was back-
crossed to a C3H/He strain female (C3H, Charles River Laboratories). The C3H
strain was used because this strain has been used extensively by others in exam-
ining circadian behavioral responses to melatonin (2, 3, 9), and this strain has
rhythmic melatonin production (unlike most other inbred strains of mice; see
reference 11). In each generation, heterozygous males were selected and crossed
to C3H females. After backcrossing was done for 10 generations, heterozygous
male and female mice were interbred to produce wild-type and Mel1a receptor-
deficient lines which produce rhythmic melatonin as previously reported (42).
Similarly, a male Mel1b receptor-deficient mouse (on the isogenic, 129/sv
genetic background) was bred to a C3H female. Heterozygous male offspring
from each generation were backcrossed to C3H females for six generations of
backcrossing, at which time male and female heterozygotes were interbred to
produce wild-type and Mel1b receptor-deficient lines on the C3H background.
Finally, Mel1a receptor-deficient mice on the C3H genetic background were
crossed with the Mel1b receptor-deficient mice on the C3H background to gen-
erate Mel1a/Mel1b double-mutant mice on a C3H genetic background.
Multiunit recordings. Multiunit recordings of SCN electrical activity were
performed as previously described (14, 23). Briefly, hypothalamic slices were
prepared from adult male mice maintained in a 12-h light:12-h dark lighting
cycle. Animals were euthanatized 2 to 5 h after lights-on. Brains were rapidly
dissected and placed into artificial cerebrospinal fluid medium (ACSF) contain-
ing 116.3 mM NaCl, 5.4 mM KCl, 1.0 mM NaH2PO4, 26.2 mM NaHCO3, 1.8 mM
CaCl2, 0.8 mM MgSO4, 24.6 mM dextrose, and 5-mg/liter gentamicin sulfate (pH
7.5). Slices (400 m thick) were prepared using a tissue chopper. Electrical
activity was recorded using a Teflon-coated platinum-iridium wire electrode as
previously described (14, 23).
Experiments were performed on the second day in vitro, 24 h after prepa-
ration of the slices. Slices were exposed to vehicle (0.1% ethanol in ACSF) and
then to escalating concentrations of melatonin (0.1 to 100 nM) in ACSF con-
taining a maximum of 0.1% ethanol. Data are expressed as percent change in
electrical activity at the 100-nM dose. Experiments were conducted without
knowledge of the genotypes of the animals. These studies were conducted on
wild-type and homozygous Mel1b-mutant mice on the 129/sv genetic background.
Cyclic AMP response element binding protein (CREB) phosphorylation. Pi-
tuitary adenylyl cyclase activating peptide (PACAP) is a transmitter of the
retinohypothalamic tract, the pathway that conveys light-dark information from
the retina to the SCN (17). PACAP appears to modulate the effects of glutamate
on the SCN (17, 40). In vitro application of PACAP to SCN slices induces
phosphorylation of CREB on serine residue 133 (20, 40, 41). Phosphorylated
CREB (pCREB) is thought to play an important role in the photic regulation of
gene expression in the SCN, including the light-induced expression of c-fos and
the mPeriod genes (14, 38, 40). Melatonin reduces PACAP-induced pCREB
immunoreactivity in SCN slices in a dose-dependent manner (20, 40, 41, 42).
Melatonin may thus subtly modulate photic sensitivity of the SCN circadian
clock.
Melatonin inhibition of the PACAP-induced CREB phosphorylation state was
studied as previously described (41). Briefly, 400-m coronal brain slices con-
taining the SCN were collected 2 to 6 h after lights-on and maintained in
oxygenated medium (145 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.8 MgCl2, 10
mM HEPES, and 10 mM glucose [pH 7.35]). At the time corresponding to
Zeitgeber Time 10 (ZT10, e.g., 10 h after lights-on in the colony room), slices
were treated with PACAP (100 nM) or vehicle. Slices were pretreated with
melatonin (1 or 100 nM) or vehicle for 15 min prior to PACAP application.
Fifteen minutes after PACAP application, slices were fixed with 4% paraformal-
dehyde. Slices were fixed for 12 to 16 h and then cryo-protected (20% sucrose in
phosphate-buffered saline) and sectioned at 14-m thickness on a cryostat.
Sections were mounted on gelatin-coated slides and stored at 20°C until pro-
cessed for immunohistochemical detection of CREB phosphorylated at serine
133 (pCREB). pCREB was detected by use of a commercially available, poly-
clonal antibody (Upstate Biotechnology, Lake Placid, N.Y.) at a dilution of
1:1,000. Immunoreaction was visualized with a standard avidin-biotin labeling
method (Vector Labs, Burlingame, Calif.) with diaminobenzidine as a chromo-
gen.
Semiquantitative analysis was performed as previously described (41). Briefly,
images were digitized (VIDAS, Kontron, Germany), and background staining
was defined as the lower threshold. Within the area of the SCN, all cell nuclei
showing a pCREB immunoreaction exceeding the threshold were marked. Im-
munoreactive nuclei were then counted in three sections per animal in a blind
manner. The average of six values (number of immunoreactive nuclei per uni-
lateral SCN per 14-m section) was calculated for each animal.
It is not known whether melatonin alters the number of nuclei immunoreactive
for pCREB by a reduction in the rate of phosphorylation of CREB or by
activation of a phosphatase. In this report, “CREB phosphorylation” is used to
indicate the static state of CREB phosphorylation (e.g., density of pCREB-
immunoreactive nuclei), not the rate at which CREB is phosphorylated.
Nucleotide sequence accession number. The cDNA sequence for the mouse
Mel1b receptor that was determined in this study has been deposited in GenBank
(accession number AY145850).
RESULTS
Isolation and characterization of the mouse Mel1b receptor
cDNA. The mouse Mel1b receptor cDNA sequence was deter-
mined from genomic DNA and confirmed by amplification of
the receptor cDNA from brain RNA (see Materials and Meth-
ods for discussion of discrepancies between our sequence and
other database entries).
The deduced amino acid sequence of the Mel1b receptor has
features shared by other members of the melatonin receptor
subfamily of G protein-coupled receptors (Fig. 2). Specifically,
the amino acid sequence of the mouse Mel1b receptor is highly
related to the human Mel1b receptor, with which it shares 79%
identity. The other closely related sequences identified by
BLAST searches of the GenBank database are fragments of
the Mel1b receptor cDNA from other species, including the
Northern pike Mel1b receptor cDNA (12). Amino acid identity
of the mouse Mel1a and Mel1b receptors is 50.8%.
The mouse Mel1b receptor sequence also has several fea-
tures conserved in the melatonin receptor family within the
superfamily of G protein-coupled receptors. A highly con-
served sequence just downstream from the third transmem-
brane domain (NRYC[C/Y]ICHS) is distinctive; most other
receptor families have DRY or ERY in place of NRY (33, 45).
In transmembrane domain 7, the melatonin receptor family
shares a characteristic motif (NA[I/V][I/V]Y) rather than
NPXXY. The presence of potential a N-linked glycosylation
site in the amino-terminal, putative extracellular domain of the
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protein is also a common feature of the melatonin receptor
family. Finally, with respect to gene structure, the location of
the splice site between exons 1 and 2 is also conserved among
all mammalian melatonin receptor genes that have been ex-
amined (32, 34, 47).
To determine the relative affinity and specificity of mouse
melatonin receptors, the characteristics of the mouse Mel1a
and Mel1b receptor cDNAs were examined in parallel.
125I-
MEL binding to transfected COS7 cells revealed that the af-
finity of the mouse Mel1b receptor is significantly lower than
the affinity of the mouse Mel1a receptor (Mel1b, Kd (mean 
standard error of the mean [SEM]) 199.9 13.4 pM [n 4];
Mel1a, KD  59.3  18.3 pM [n  2]). Competition experi-
ments with several drugs revealed that the rank order of po-
tency was as expected for a member of the melatonin receptor
gene family, e.g., 2-iodomelatonin  melatonin  6-chlorome-
latonin  N-acetylserotonin (Table 1). The relative affinity of
the receptor subtypes as well as the rank order of drug potency
for inhibiting 125I-MEL binding are similar to the characteris-
tics of the human Mel1a and Mel1b receptors (30).
It is noteworthy that the mouse Mel1b receptor encodes a
functional receptor, as inferred from its sequence and con-
firmed in radioreceptor assays. This is in contrast to the Mel1b
receptor gene in several hamster species, including Siberian
and Syrian hamsters, in which nonsense mutations disrupt the
receptor cDNA (see reference 47 and GenBank accession
number AY145849).
Targeted disruption of the mouse Mel1b receptor gene. Mice
with targeted disruption of the Mel1b receptor gene are viable
and fertile. This is not unexpected; most inbred strains of mice
do not produce melatonin as a result of genetic defects in the
synthetic enzymes (11, 35), and removal of the pineal gland,
the source of circulating melatonin, does not have major phys-
iological effects (except in species in which melatonin is in-
volved in the seasonal regulation of reproduction).
Observations of locomotor activity rhythms of Mel1b recep-
tor-deficient mice and wild-type controls placed in constant
darkness revealed no robust circadian phenotype; e.g., activity
rhythms persisted in homozygous Mel1b receptor-deficient
mice in constant conditions, with a period length similar to that
observed in controls (data not shown). Preliminary attempts to
use daily or repeated daily injections of melatonin to phase
shift the locomotor activity rhythm of wild-type mice were
unsuccessful, preventing us from employing an in vivo assay of
melatonin receptor function. Instead, in vitro assays of mela-
tonin receptor function were employed.
Melatonin inhibits multiunit activity via the Mel1a receptor.
Inhibition of SCN multiunit activity by melatonin was unaf-
fected in mice with targeted disruption of the Mel1b receptor
(Fig. 3). In contrast, the acute suppressive effect of melatonin
was absent in mice homozygous for targeted disruption of the
Mel1a receptor (23; [data replotted for comparison in Fig. 3]).
Thus, the Mel1a receptor alone appears to mediate the sup-
pressive effect of melatonin on SCN neuronal firing rate.
Both melatonin receptor subtypes contribute to regulation
of CREB phosphorylation. Previous studies have shown that
melatonin reduces the levels of PACAP-induced CREB phos-
phorylation at low concentrations (20, 40, 41). In wild-type
mice, physiological concentrations of melatonin (1 nM) in-
hibit the level of phosphorylated CREB by70%. In mice with
targeted disruption of the Mel1a melatonin receptor, the re-
FIG. 2. The mouse Mel1b receptor sequence. The sequence of the mouse Mel1b receptor has been aligned with other members of the melatonin
receptor gene family: mouse Mel1b (present work), human Mel1b (30), mouse Mel1a (34) (NP_032665), and human Mel1a receptor (29)
(NP_005949). Putative transmembrane domains are indicated by underlining in the sequence for the mouse Mel1b receptor. Gaps introduced to
optimize alignment are indicated by dashes. Consensus sequence is defined as residues that are identical in all four of the sequences shown.
TABLE 1. Inhibition constants for mouse Mel1a and
Mel1b receptor cDNAs
a
Compound
Ki (no. of experiments) for:
Mel1a Mel1b
2-Iodomelatonin 0.045 0.005 (4) 0.159 .017 (4)
Melatonin 0.438  0.169 (3) 2.853 0.665 (3)
6-Chloromelatonin 4.053 1.371 (3) 8.903 1.640 (3)
N-acetylserotonin 638 (1) 296 (1)
a Inhibition constants (Ki values) are expressed as means  SEM, in nanomo-
lar concentrations.
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sponse to 1 nM melatonin is absent, but a residual effect of
melatonin is apparent at higher melatonin concentrations (Fig.
4A, consistent with previously published results [41]). This
higher-threshold response to melatonin appears to be medi-
ated by the Mel1b receptor, as the Mel1b-preferring antagonist,
4P-PDOT (8), blocks the high-threshold response (41). In mice
with targeted disruption of both Mel1a and Mel1b receptor
genes, the residual response to high concentrations of melato-
nin is completely absent (Fig. 4B). These data indicate a dual
regulation of the CREB phosphorylation state in the SCN: the
Mel1a receptor mediates responses to low concentrations of
the hormone, while the residual response at higher concentra-
tions is mediated by the Mel1b receptor. The presence of a
functional Mel1a receptor that would mediate low-threshold
responses precluded assessing the effect of disruption of the
Mel1b receptor alone.
DISCUSSION
Melatonin has subtle actions on circadian rhythmicity in
mice and in other mammals (46). Mice with targeted disrup-
tion of either Mel1a or Mel1b receptor subtype, or the double
mutants, do not have a striking overt phenotype. Examination
of melatonin receptor-mediated responses does reveal a func-
tional effect of each of the receptor subtypes, however. The
Mel1a receptor is necessary for the suppressive effect of mel-
atonin on SCN neuronal firing (23). Targeted disruption of the
Mel1b receptor did not alter this response to melatonin. With
respect to inhibition of the PACAP-induced CREB phosphor-
ylation state, melatonin acts through the Mel1a receptor at low
concentrations of the hormone (41) (present results). An effect
of higher concentrations of melatonin is apparent in Mel1a
receptor-deficient mice, and this response is blocked by treat-
ment with the Mel1b receptor antagonist, 4P-PDOT (41). Con-
sistent with this dual regulation, we report here that the SCN
of Mel1a-Mel1b double-mutant mice is completely unrespon-
sive to melatonin, even at the higher (100 nM) melatonin
concentrations.
One of the in vitro assays used previously to assess the effects
of melatonin on the circadian clock involves monitoring the
effect of melatonin on the phase of single-unit firing rate
rhythms in SCN slices (19, 23, 26, 47). Liu et al. (23) found that
melatonin and 2-iodomelatonin phase-shifted the circadian
FIG. 3. Inhibition of SCN multiunit activity by melatonin. Inhibi-
tion of SCN electrical activity by melatonin (0.1 to 100 nM) was
assessed during midday. Data are plotted as the percent inhibition of
electrical activity observed at the 100 nM dose relative to the level of
electrical activity from the same slice exposed to vehicle. The left set of
bars shows that the inhibition of SCN electrical activity is absent in
Mel1a receptor-deficient (/) mice (data replotted from reference
23; sample sizes 7 to 11 per group). Right bars show inhibition of SCN
activity in experiments conducted for this study, using Mel1b receptor-
deficient mice (/) (n  6) and wild-type control (/) (n  11)
mice. The inhibition of electrical activity in each group was significant
(P 	 0.0001, one-sample t tests, versus 0% inhibition), and there was
no significant difference between the Mel1b / and Mel1b /
groups (t test, P  0.2).
FIG. 4. Inhibition of CREB phosphorylation levels by melatonin.
Semiquantitative densitometric analysis shows that melatonin reduces
the number of pCREB-immunoreactive nuclei in PACAP-treated
SCN slices. Values represent labeled nuclei per unilateral SCN and are
the mean SEM for four to five animals per group. In wild-type mice,
melatonin (1 nM) reduces PACAP-induced CREB phosphorylation by
70% (41). In contrast, a 1 nM concentration had no significant effect
on mice with targeted disruption of the Mel1a melatonin receptor
(Mel1a /) (A). At higher melatonin concentrations (100 nM), a
more complete suppression occurs even in mice with disruption of the
Mel1a receptor subtype (A) (far right). This residual, higher-threshold
response is absent in mice with targeted disruption of both the Mel1a
and Mel1b receptors (B). , significant difference between vehicle
control and PACAP treatment (P 	 0.002, t test); , significant dif-
ference versus PACAP group (P 	 0.01, Dunnett’s test); NS, not
significantly different from PACAP group (P  0.05, Dunnett’s test).
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rhythm of SCN single-unit activity even in mice with targeted
disruption of the Mel1a receptor, although the magnitude of
response was lower in the Mel1a receptor-deficient mice at low
ligand concentrations. The response persisting in Mel1a recep-
tor-deficient mice was mediated by a pertussis toxin-sensitive
mechanism, indirectly implicating Mel1b receptors as mediat-
ing the higher-threshold response. More recently, Hunt et al.
(19) reported that the Mel1b receptor subtype mediates the
phase-shifting effect of melatonin in the rat SCN, based on
studies using subtype-selective antagonists. In contrast, SCN
slices from hamsters lacking a functional Mel1b receptor (due
to a naturally occurring nonsense mutation) respond to mela-
tonin with phase shifts in single-unit activity (47). These di-
verse results from the single-unit assay indicate either that
there are pronounced species differences in the melatonin re-
ceptor subtype mediating the phase shifting response or, more
likely, that there is functional redundancy between the recep-
tor subtypes.
While this assay system has been used successfully by our
associates and others in the past, in preliminary studies we
were unable to obtain reliable single-unit activity rhythms,
even with commercially reared wild-type mice, at the time we
attempted to examine the responses of Mel1b receptor-defi-
cient mice (C. Liu and S. M. Reppert, unpublished data). In
the absence of a robust rhythm with clearly defined phase,
assessment of the impact of melatonin on circadian phase was
not possible.
We were also unable, in preliminary experiments, to dem-
onstrate a consistent effect of melatonin on locomotor activity
rhythms in vivo, even in wild-type mice with the C3H genetic
background. This strain has previously been reported to exhibit
phase shifts in response to melatonin treatment (2, 3, 9). The
mean phase shift occurring in the paradigm described by
Dubocovich and colleagues is a less than 1.0-h total shift with
daily injections of melatonin for 3 days. Behavioral arousal
(such as would occur coincident with handling the animal for
injection) has an effect on the rodent circadian system that
appears to be as robust as the effect of melatonin (18, 28). In
our hands, melatonin injection paradigms did not elicit consis-
tently detectable phase shifts in mice. We were thus unable to
use the mutant mice to directly test the hypothesis (9) that the
Mel1b receptor mediates behavioral phase shifts.
Data from other systems suggest that both Mel1a and Mel1b
receptors contribute to responses to the hormone. Vascular
responses to melatonin occurring at low concentrations are
mediated primarily by the Mel1a receptor, with a Mel1b-medi-
ated response occurring at higher concentrations (6, 37). This
directly parallels our findings regarding the dose-related inhi-
bition of PACAP-induced CREB phosphorylation in the SCN.
The acute suppressive effect of melatonin on SCN neuronal
firing is mediated by the Mel1a receptor. The Mel1b receptor
appears to mediate inhibition of firing in the rat hippocampus,
which, unlike the mouse hippocampus, has a significant level
of melatonin receptor binding (44). A melatonin-regulated
rhythm in mPeriod1 gene expression in the pars tuberalis of
the pituitary is abolished by removal of the pineal gland in
hamsters (27); the absence of a functional Mel1b melatonin
receptor gene in this species implicates the Mel1a receptor.
Consistent with this proposal, pinealectomy or targeted dis-
ruption of the Mel1a receptor gene in mice that have rhyth-
mic pineal melatonin synthesis disrupts rhythmic mPer1 ex-
pression in the pars tuberalis (42). These findings suggest
that the expression of melatonin receptor subtypes varies by
tissue and indicate the possibility of functional redundancy
when the receptor subtypes are coexpressed.
In summary, targeted disruption of the Mel1b receptor does
not have a profound impact on the circadian system of mice.
Our data from examining melatonin inhibition of the level of
CREB phosphorylation in PACAP-treated SCN slices indicate
that the Mel1a receptor mediates the majority of this response
to the hormone. At higher melatonin concentrations, a resid-
ual impact of melatonin, acting via the Mel1b receptor, is ap-
parent. This difference in the relative contribution of the re-
ceptor subtypes is likely not due to differences in the affinity of
the receptors per se, but instead may derive from differences in
the levels of receptor expression directed by the two genes or
by differences in coupling to second messenger pathways. The
Mel1a receptor accounts for all the melatonin receptor binding
detected in mouse brain by in vitro autoradiography (23). The
Mel1a receptor, being much more highly expressed, may me-
diate most responses to the hormone in mice. The Mel1b re-
ceptor can also contribute to responses in those tissues in
which it is expressed. The availability of mice with targeted
disruption of Mel1a, Mel1b, and both receptor subtypes will
allow a genetic approach to dissection of additional melatonin
receptor-mediated responses.
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